Category - Developments

Developments

Evaxion reports positive one-year Phase 2 data on personalized cancer vaccine

Evaxion Biotech (NASDAQ:EVAX) has announced positive one-year data from its Phase 2 trial of the AI-designed personalized cancer vaccine, EVX-01, a potential treatment for melanoma. The data, from a one-year interim...

September 16, 2024

Developments

Cidara’s workforce restructuring enables focus on clinical development

Cidara Therapeutics (NASDAQ:CDTX) has announced a planned workforce reduction, impacting approximately 30% of the company’s employees, enabling the company to reduce capital needs and concentrate on the clinical...

September 13, 2024

Developments

Tenon prepares to launch new joint fixation device with 30% reduction in implant width

Tenon Medical (NASDAQ:TNON) announced the limited alpha launch of its new Catamaran SE SI Joint Fusion System in early Q4. The company aims to gather initial user feedback from a select group of physicians to support a...

September 13, 2024

Developments

Aura announces positive Phase 2 EOS results evaluating bel-sar for CM

Aura Biosciences (NASDAQ:AURA) has announced positive Phase 2 end-of-study (EOS) results evaluating the safety, tolerability, and efficacy of bel-sar (AU-011) for the first-line treatment of early-stage choroidal...

September 12, 2024

Developments

Vor Bio reports data validating shielded transplants and early evidence of patient benefit

Vor Bio (NASDAQ:NOR) announced new data from its ongoing Phase 1/2 study of VBP101 in relapsed/refractory AML patients, demonstrating reliable engraftment, shielding from Mylotarg toxicity, a broadened therapeutic...

September 6, 2024

Developments

Ocuphire doses first participants in Phase 3 presbyopia study

Ocuphire Pharma (NASDAQ:OCUP) has initiated its VEGA-3 Phase 3 trial, evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia, with its first dose. Topline results are expected in the first half of 2025...

September 6, 2024

Developments

NIH awards TransCode with $2 million grant for lead therapeutic

TransCode Therapeutics (NASDAQ:RNAZ) announced that the National Institutes of Health (NIH) has awarded the company a $2 million Direct to Phase II Small Business Innovation Research grant to support the clinical...

September 5, 2024

Developments

Aurinia reports first participant dosed milestone for potential therapy in autoimmune diseases

Aurinia Pharmaceuticals (NASDAQ:AUPH) has announced that the first participant has been dosed in its Phase 1a study of AUR200, a differentiated, best-in-class potential therapy for autoimmune diseases targeting B-cell...

September 5, 2024

Developments

Valneva and Pfizer announce positive Phase 2 data for Lyme disease booster candidate

Valneva SE (NASDAQ:VALN) and Pfizer (NYSE:PFE) have announced positive Phase II immunogenicity and safety data from a second booster dose of the VLA15 Lyme disease vaccine candidate, administered one year after the...

September 3, 2024

Developments

Praxis reports positive topline results from study of relutrigine in developmental epilepsies

Praxis Precision Medicines (NASDAQ:PRAX) has announced positive topline results from its EMBOLD Phase II proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy...

September 3, 2024

Category - Developments

Subscribe